同义名 :	NM441; AF 3013
	CAS号 :	123447-62-1
	货号 :	A151816
	分子式 :	C21H20FN3O6S
	纯度 :	98%
	分子量 :	461.46
	MDL号 :	MFCD00864847
	存储条件：	Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Prulifloxacin is a new fluoroquinolone with indications in the treatment of urinary tract infection and acute exacerbations of chronic bronchitis[3]. Prulifloxacin is the active metabolite of ulifloxacin with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for prolongation of the QT interval; the CNS(central nervous system) penetration is negligible; in women prulifloxacin does not affect the lactobacillary component of the vaginal microbiota, lowering the risk of genito-urinary tract infections[4]. In well-designed clinical trials, prulifloxacin 600 mg administered once daily for 10 days in patients with AECB (acute exacerbations of chronic bronchitis) showed good clinical and bacteriological efficacy[5].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00392574	Acute Gastroenteritis in Adult... 展开 >> Travelers 收起 <<	Phase 3	Completed	-	United States, Pennsylvania ... 展开 >> INC Research New Hope, Pennsylvania, United States, 18938 收起 <<
NCT00448422	Acute Bacterial Gastroenteriti... 展开 >>s 收起 <<	Phase 3	Completed	-	India ... 展开 >> Goa Medical College Bambolim, Goa, India 收起 <<
NCT02130713	Chronic Bacterial Prostatitis	Phase 4	Completed	-	Italy ... 展开 >> policlinico Umberto I - Department of Gynecological-Obstetrics Sciences and Urological Sciences Roma, Italy, 00161 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	2.17mL 0.43mL 0.22mL	10.84mL 2.17mL 1.08mL	21.67mL 4.33mL 2.17mL

参考文献

[1]Chen Y, Yang H, et al. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. Chemotherapy. 2012;58(3):249-56. [2]Rafailidis PI, Polyzos KA, et al. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents. 2011 Apr;37(4):283-90. [3]Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2007;2(1):27–31 [4]Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007;30 Suppl 2:S109–S112 [5]Cazzola M, Salvatori E, Dionisio P, Allegra L. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther. 2006;19 Suppl 1:30–37